As of May 29, 2025, Althea Group Holdings Ltd (AGH.AX) reports a ROE (Return on Equity) of -10209.24%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Althea Group Holdings Ltd's ROE (Return on Equity)
Over recent years, Althea Group Holdings Ltd's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-06-30 | -10209.24% |
| 2023-06-30 | -46.11% |
| 2022-06-30 | -29.25% |
| 2021-06-30 | -35.24% |
| 2020-06-30 | -32.02% |
This fluctuation highlights how Althea Group Holdings Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing Althea Group Holdings Ltd's ROE (Return on Equity) to Peers
To better understand Althea Group Holdings Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Althea Group Holdings Ltd (AGH.AX) | -10209.24% |
| Zelira Therapeutics Ltd (ZLD.AX) | 809.95% |
| MGC Pharmaceuticals Ltd (MXC.AX) | 281.28% |
| Recce Pharmaceuticals Ltd (RCE.AX) | 185.45% |
| Rhinomed Ltd (RNO.AX) | 170.29% |
| Vita Life Sciences Ltd (VLS.AX) | 16.78% |
Compared to its competitors, Althea Group Holdings Ltd's ROE (Return on Equity) is lower than all peers, which may indicate less effective deployment of shareholders' capital.